Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies
A recent survey examines the industry's views on the chief challenges and technologies in drug delivery and formulation development.

Pharmaceutical Technology
Volume 36, Issue 4

Seeking solutions

In addressing problems of bioavailability and solubility, "there are two dimensions to which to address solubility of poorly soluble drugs, the drug substance and drug product," says Kurt Nielsen, PhD and senior vice-president, innovation and growth with Catalent Pharma Solutions, in commenting on the survey results. With respect to the drug substance, he points to various solutions, such as optimizing the salt form or solid-state form (i.e., polymorph or co-crystal). Slight modifications to the drug substance also can be made to improve solubility, such as converting the drug to a prodrug, or by reducing the particle size of the drug substance, explains Nielsen.

With respect to the drug product, Nielsen says that various methods can improve solubility, ranging from straightforward strategies, such as solubilizing agents (e.g., surfactants and polymers) to more complex solutions where site-specific drug release is required to address such issues as poor stability of the drug in the stomach or pre-systematic metabolism in certain locations in the gastrointestinal tract. As with the drug substance, particle engineering can be used to not only optimize solubility but also to modify or control the release of the drug, he adds. In sum, these strategies seek to address the key aspects of solubility, permeability, and site of absorption.

On a dosage form level, various approaches may be used. "Liquid-based dosage forms, such as softgels, dispersion-based dosage forms through hot-melt or spray-dried dispersions, and drug layering and coating can be used to improve solubility and bioavailability of oral dosage forms," says Nielsen. If bioavailability is still a problem, other routes of administration, such as transdermal, buccal, and sublingual drug delivery can be considered.


1. Catalent–Pharmaceutical Technology Landscape Drug Delivery Survey (December 2011).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here